NGAL in trans-catheter aortic valve implantation on and off renalguard

Sapir Sadon, Yaron Arbel, Ariel Banai, Keren Lee Rozenfeld, Phillipe Taieb, Aviram Hochstadt, Yacov Shacham, Shmuel Banai, Ariel Finkelstein, Ilan Merdler

Research output: Contribution to journalArticlepeer-review


Introduction: Acute kidney injury (AKI) is a well-known complication post invasive cardiac procedures. RenalGuard system has been shown to reduce the risk of AKI in high-risk patients by evacuating iodine-based contrast material rapidly. Neutrophil gelatinase-associated lipocalin (NGAL) is a glycoprotein stored in granules of mature neutrophils and is released to the blood stream due to acute tubular damage. This report examined the biomarker as a sub study of the randomized sham control study REDUCE-AKI in the setting of Trans-Aortic Valve Implantation (TAVI). Methods: Venous blood was drawn from 27 patients. Blood was drawn at designated time intervals: before the procedure, after 12 hours and after 24 hours. Patients were randomly allocated to active versus sham RenalGuard activity. Results: There was no difference between baseline and 24 hours levels in NGAL values (ng/mL) in the sham group (median 70.3 IQ 21.5, 176.6) versus the active group (median 46.9, IQR 1.3, 127.7) (P = 0.259). There was also no association between NGAL and clinical complications. Conclusion: Forced diuresis with matched hydration does not prevent AKI in patients undergoing TAVI and measuring NGAL correlates with these findings.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalSigna Vitae
Issue number4
StatePublished - Jul 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 The Authors. Published by MRE Press.


  • AKI
  • NGAL
  • RenalGuard
  • TAVI
  • TAVR


Dive into the research topics of 'NGAL in trans-catheter aortic valve implantation on and off renalguard'. Together they form a unique fingerprint.

Cite this